Full Press Release Details
RELEASE - REGULATED INFORMATION
November 2021, 11:00 p.m. CET
Shareholder Transparency Declarations
CA, and HERSTAL, BELGIUM - 15 November 2021 - MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company"
or "MDxHealth"), a commercial-stage precision diagnostics company, announces today
in accordance with Article 14 of the Belgian Act of 2 May 2007 on the disclosure of important participations in issuers of which shares
are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act"), that
it received the following notifications of significant shareholdings.
was notified that the number of shares with respect to which Bleichroeder LP can exercise voting rights actively crossed above the threshold
of 10% of the outstanding shares and voting rights of MDxHealth on 4 November 2021. Notably, it follows from the notification that an
aggregate of 21,783,330 shares of MDxHealth, representing 13.97% of the 155,969,226 outstanding shares and voting rights of MDxHealth
(taking into account the capital increase that was announced on 4 November 2021 and that was completed on 8 November 2021), is held through
the following entities: 21 April Fund LP (5,266,830 shares), 21 April Fund LTD (13,599,830 shares), Hill Family Alternative Investments
LLC (2,500,000 shares), and White Clover SA (416,670 shares) (the "Funds"). The notification also stated that the voting
rights attached to the shares are exercised on behalf of the Funds by the investment adviser Bleichroeder LP, a Delaware limited partnership,
at its discretion, in the absence of specific instructions, that Bleichroeder Holdings LLC, a Delaware limited liability company, is
the general partner of Bleichroeder LP, that, as the general partner, Bleichroeder Holdings LLC holds control over voting rights of Bleichroeder
LP, and that Bleichroeder Holdings LLC is not a controlled entity.
was notified that the number of shares with respect to which Soleus Capital Management, L.P. can exercise voting rights actively crossed
below the threshold of 5% of the outstanding shares and voting rights of MDxHealth on 5 November 2021. Notably, it follows from the notification
that 5,829,261 shares of MDxHealth, representing 4.92% of 118,469,226 outstanding shares and voting rights of MDxHealth (which, taking
into account the capital increase that was announced on 4 November 2021 and that was completed on 8 November 2021, represents 3.97% of
155,969,226 outstanding shares and voting rights of MDxHealth), are held through Soleus Capital Master Fund, L.P. The notification also
stated that the voting rights attached to the shares are exercised by the investment advisor Soleus Capital Management, L.P., a Delaware
limited partnership, at its discretion, in the absence of specific instructions, that Soleus Capital Master Fund, L.P. is a limited partnership
formed in the Cayman Islands, that Soleus Capital Management, L.P. is controlled by a sole general partner, Soleus GP, LLC, a Delaware
limited liability company, and that Soleus GP, LLC is controlled by its sole member, Mr. Guy Levy.
further information, reference is made to the information published on MDxHealth's website (http://www.mdxhealth.com/investors/shareholder-information).
to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial
Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights
attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every
subsequent multiple of 5%, of the total number of voting rights in the Company.
is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis
and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies
and assist physicians with the diagnosis of urologic cancers and prognosis of recurrence risk. The Company's European headquarters are
in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and U.S. headquarters and laboratory operations based in
and linkedin.com/company/mdxhealth.
| For more information: | |
| MDxHealth | |
| info@mdxhealth.com |
MDxHealth logo, MDxHealth, ConfirmMDx and SelectMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and
service marks are the property of their respective owners.